TY - JOUR
T1 - Molecular PET/CT Profiling of ACE2 Expression In Vivo
T2 - Implications for Infection and Outcome from SARS-CoV-2
AU - Zhu, Hua
AU - Zhang, Hanwen
AU - Zhou, Nina
AU - Ding, Jin
AU - Jiang, Jinquan
AU - Liu, Teli
AU - Liu, Ziyu
AU - Wang, Feng
AU - Zhang, Qian
AU - Zhang, Zhuochen
AU - Yan, Shi
AU - Li, Lei
AU - Benabdallah, Nadia
AU - Jin, Hongjun
AU - Liu, Zhaofei
AU - Cai, Lisheng
AU - Thorek, Daniel L.J.
AU - Yang, Xing
AU - Yang, Zhi
N1 - Publisher Copyright:
© 2021 The Authors. Advanced Science published by Wiley-VCH GmbH
PY - 2021/8/18
Y1 - 2021/8/18
N2 - Rapid progress has been made to identify and study the causative agent leading to coronavirus disease 2019 (COVID-19) but many questions including who is most susceptible and what determines severity remain unanswered. Angiotensin-converting enzyme 2 (ACE2) is a key factor in the infection process of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this study, molecularly specific positron emission tomography imaging agents for targeting ACE2 are first developed, and these novel agents are evaluated in vitro, in preclinical model systems, and in a first-in-human translational ACE2 imaging of healthy volunteers and a SARS-CoV-2 recovered patient (NCT04422457). ACE2 expression levels in different organs in live subjects are quantitatively delineated and observable differences are measured in the patient recovered from COVID-19. Surprising sites of uptake in the breast, reproductive system and very low uptake in pulmonary tissues are reported. This novel method can add a unique tool to facilitate SARS-CoV-2 related research and improve understanding of this enigmatic disease. Molecular imaging provides quantitative annotation of ACE2, the SARS-CoV-2 entry receptor, to noninvasively monitor organs impacted by the COVID-19.
AB - Rapid progress has been made to identify and study the causative agent leading to coronavirus disease 2019 (COVID-19) but many questions including who is most susceptible and what determines severity remain unanswered. Angiotensin-converting enzyme 2 (ACE2) is a key factor in the infection process of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this study, molecularly specific positron emission tomography imaging agents for targeting ACE2 are first developed, and these novel agents are evaluated in vitro, in preclinical model systems, and in a first-in-human translational ACE2 imaging of healthy volunteers and a SARS-CoV-2 recovered patient (NCT04422457). ACE2 expression levels in different organs in live subjects are quantitatively delineated and observable differences are measured in the patient recovered from COVID-19. Surprising sites of uptake in the breast, reproductive system and very low uptake in pulmonary tissues are reported. This novel method can add a unique tool to facilitate SARS-CoV-2 related research and improve understanding of this enigmatic disease. Molecular imaging provides quantitative annotation of ACE2, the SARS-CoV-2 entry receptor, to noninvasively monitor organs impacted by the COVID-19.
KW - angiotensin-converting enzyme 2
KW - human
KW - positron emission tomography imaging
KW - severe acute respiratory syndrome coronavirus-2
KW - translational research
UR - http://www.scopus.com/inward/record.url?scp=85108799807&partnerID=8YFLogxK
U2 - 10.1002/advs.202100965
DO - 10.1002/advs.202100965
M3 - Article
C2 - 34174177
AN - SCOPUS:85108799807
SN - 2198-3844
VL - 8
JO - Advanced Science
JF - Advanced Science
IS - 16
M1 - 2100965
ER -